InfraCom's Q1 came in below Redeye's expectations. Net sales fell 3% y/y to SEK199m, missing Redeye'...
* Q1 EBIT of SEK -45m, vs. ABGSC of SEK +18m and cons.
Suominen’s operating environment remains quite challenging, but sales volumes and mix should be incr...
Catella's Q1 2026 print came in materially below both Redeye's below-consensus estimate and FactSet ...
* Q1: Organic growth of +7% despite tough comps (vs.
Redeye updates on EG7 after Q1-results where we expect strong performance in the remainder of the ye...
* Approval to initiate the financed TOTEMS study * Patient enrolment imminent Gabather has announce...
Redeye updates its estimates and valuation following Navigo releasing its Q1 2026 report.
OHB remains a compelling way to gain listed exposure to Europe’s sovereign space build-out.
GFT's Q1 26 came in bang in line with our expectations.
Raute’s low order book remains an issue for now, but in our view chances are European orders will be...
Redeye provides an update following Truecaller’s Q1 2026 results, in which net sales provided a slig...
Investors House's Q1 report was burdened by one-off costs, and both the Real Estate and Services seg...
Redeye retains its positive view of Freja following the Q1 report.
Q1 net sales and adjusted EBITDA were slightly below our expectations.
Q1 adjusted EBITDA was clearly higher and adjustment items significantly lower than we forecast.
* Strong margins (19% adj. EBIT margin), improved ACV * We raise '26e/'27e/'28e EBIT by 20%/6%/5% on...
Etteplan's Q1 was clearly softer than expected, with all three service areas missing our EBITA estim...
Premium Snacks levererade ett starkt Q1’26 med en tillväxt om 17,9 % och förbättrad lönsamhet, trots...
Redeye comments on the acquisition of Superior and the directed rights issue.
Redeye comments on Active Biotech's first quarter report.